GSK has agreed to acquire global rights to a trispecific T cell engager program for multiple myeloma from Chimagen Biosciences in a deal with a potential value of up to $750 million.
GSK will pay Chimagen an upfront fee and may make additional development and commercial milestone payments. The companies did not disclose the upfront payment or the value of individual milestones. The transaction remains subject to customary closing conditions.
The program is expected to enter Phase I clinical trials in 2027. GSK plans to develop and commercialize the asset for multiple myeloma.
The trispecific T cell engager is designed to bind T cells and two tumor-associated antigens. GSK said the program is intended to pursue deeper and more durable responses and improved tolerability compared with existing T cell engagers.
T cell engagers have shown activity in multiple myeloma but can have tolerability challenges, according to GSK. The company said the asset could potentially be used more broadly and earlier in multiple myeloma treatment.
Multiple myeloma is a blood cancer. GSK said about 180,000 new cases are diagnosed globally each year. The disease is generally considered treatable but not curable and may become refractory to available therapies.
The agreement expands an existing relationship between GSK and Chimagen. GSK previously agreed to acquire CMG1A46, a clinical-stage dual CD19- and CD20-targeted T cell engager being studied in Phase I trials for B-cell malignancies and B-cell-dependent autoimmune disorders.
Chimagen is a clinical-stage biotechnology company focused on multispecific T cell engagers and NK cell engagers. GSK said the new agreement supports its blood-cancer portfolio, including its multiple-myeloma programs.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!